• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

    3.570 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 3.570
    Bid (Size) 3.200 (1,500)
    Ask (Size) 3.780 (100)
    Prev. Close 3.570
    Today's Range 3.570 - 3.570
    52wk Range 2.455 - 4.020
    Shares Outstanding 83,399,377
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Get insights into the top gainers and losers of Thursday's after-hours session. ↗
    Via Chartmill
    News headline image
    Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    N/A
    N/A
    1 Month
    +19.0%
    +19.0%
    3 Month
    +26.6%
    +26.6%
    6 Month
    -4.5%
    -4.5%
    1 Year
    +4.4%
    +4.4%

    More News

    Read More
    News headline image
    Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 12, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
    Via Benzinga
    News headline image
    Atea Pharma (AVIR) Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Atea Pharmaceuticals Inc (NASDAQ:AVIR) Reports Q3 2025 Financial Results and Business Update ↗
    Via Chartmill
    News headline image
    Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Earnings Preview ↗
    Via Benzinga
    News headline image
    Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea (AVIR) Q2 Loss Narrows 8% ↗
    Via The Motley Fool
    News headline image
    Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Top movers in Wednesday's pre-market session ↗
    Via Chartmill
    News headline image
    Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Atea Pharmaceuticals, Inc. - common stock publicly traded?
    Yes, Atea Pharmaceuticals, Inc. - common stock is publicly traded.
    What exchange does Atea Pharmaceuticals, Inc. - common stock trade on?
    Atea Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Atea Pharmaceuticals, Inc. - common stock?
    The ticker symbol for Atea Pharmaceuticals, Inc. - common stock is AVIR on the Nasdaq Stock Market
    What is the current price of Atea Pharmaceuticals, Inc. - common stock?
    The current price of Atea Pharmaceuticals, Inc. - common stock is 3.570
    When was Atea Pharmaceuticals, Inc. - common stock last traded?
    The last trade of Atea Pharmaceuticals, Inc. - common stock was at 12/31/25 04:00 PM ET
    What is the market capitalization of Atea Pharmaceuticals, Inc. - common stock?
    The market capitalization of Atea Pharmaceuticals, Inc. - common stock is 297.74M
    How many shares of Atea Pharmaceuticals, Inc. - common stock are outstanding?
    Atea Pharmaceuticals, Inc. - common stock has 298M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.